Clinical outcome in DNR/Ara-C–treated patients
| . | Total . | herg1+ . | herg1− . | P . |
|---|---|---|---|---|
| CR | 22/32 (69%) | 13/21 (61%) | 9/11(82%) | .222 |
| Relapse | 14/22 (64%) | 11/14 (79%) | 3/14 (21%) | .035 |
| Time to relapse | 14.8 ± 1.3 | 11.9 ± 2.8 | 25.3 ± 6.1 | .014 |
| . | Total . | herg1+ . | herg1− . | P . |
|---|---|---|---|---|
| CR | 22/32 (69%) | 13/21 (61%) | 9/11(82%) | .222 |
| Relapse | 14/22 (64%) | 11/14 (79%) | 3/14 (21%) | .035 |
| Time to relapse | 14.8 ± 1.3 | 11.9 ± 2.8 | 25.3 ± 6.1 | .014 |
Time to relapse is expressed in months.
Ara-C indicates aracytin; CR, complete remission; DNR, daunorubicin.